Compare WRBY & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRBY | PBLS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2021 | 2026 |
| Metric | WRBY | PBLS |
|---|---|---|
| Price | $26.87 | $27.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $31.00 | ★ $41.40 |
| AVG Volume (30 Days) | ★ 3.0M | 1.1M |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.88 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $871,905,000.00 | N/A |
| Revenue This Year | $11.16 | N/A |
| Revenue Next Year | $16.92 | $300.17 |
| P/E Ratio | $354.83 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $16.26 | $22.66 |
| 52 Week High | $31.00 | $42.49 |
| Indicator | WRBY | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 31.20 | 54.57 |
| Support Level | $21.29 | $26.42 |
| Resistance Level | $27.43 | $33.65 |
| Average True Range (ATR) | 1.52 | 2.39 |
| MACD | -0.40 | 0.77 |
| Stochastic Oscillator | 1.84 | 94.25 |
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.